Low use of long‐term hormone replacement therapy in Denmark
- 1 March 1999
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (3) , 323-328
- https://doi.org/10.1046/j.1365-2125.1999.00879.x
Abstract
Aims To examine individual use of hormone replacement therapy (HRT) in a defined population of Danish women during a 5-year period. HRT may reduce osteoporosis and cardiovascular disease in postmenopausal women, but may also have side-effects. Little is known about the use of HRT in most populations. Methods A Pharmacoepidemiological Prescription Database was used to identify all reimbursed prescriptions for HRT in the county during the period 1991 to 1995. The Danish retail pharmacies’ drug subsidy system made it possible to identify prescriptions by individual use. Results We examined 255 797 HRT prescriptions issued during the period in the County of North Jutland. Total sales reached 16.5 million defined daily doses (DDDs), purchased by 31 653 women, which corresponds to 26.9% of the female population above the age of 39 years. The annual prevalence proportion of current users rose from 10.4% to 14.8% during the study period, and the therapeutic intensity (DDD/1000 women/day) increased from 20.6 to 32.0. The mean DDD sum of systemic HRT per user was 73.4 in 1991; it and the proportion of users who received less than 90 DDD per year (83.4% in 1991) remained almost constant during the study period. The amount of oestrogen unopposed by progestin was high, 28.1% of all prescriptions. Conclusions Less than one-fifth of the study population used HRT for more than 3 months per year, and only 32.8% of the women who were new users of HRT in 1992 continued this therapy throughout the study period.Keywords
This publication has 37 references indexed in Scilit:
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Hormone replacement therapy among Danish women aged 45–65 years: Prevalence, determinants, and compliancePublished by Wolters Kluwer Health ,1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- The use of hormone replacement therapy; results of a community surveyFamily Practice, 1995
- Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone lossJournal of Bone and Mineral Research, 1992
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991
- Benefits and risks of menopausal estrogen and/or progestin hormone usePreventive Medicine, 1988
- Measurement of Drug Utilization in Sweden: Methodological and Clinical ImplicationsActa Medica Scandinavica, 1984
- Effects of 17.beta.-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cellsBiochemistry, 1981
- NATURAL ŒSTROGEN AS AN EFFECTIVE TREATMENT FOR TYPE-II HYPERLIPOPROTEINÆMIA IN POSTMENOPAUSAL WOMENThe Lancet, 1978